Abstract: A vacuum cleaner having a base, an agitator cleaner, an agitator, and a motor. The agitator extends in a longitudinal direction and is mounted to the base to rotate about a longitudinal axis of the agitator and to move between a first position in which the agitator is spaced from the agitator cleaner and a second position in which the agitator engages the agitator cleaner. The motor is operatively associated with the base and configured to rotate the agitator about the longitudinal axis of the agitator while the agitator is in the second position to remove debris from the agitator by interaction between the agitator and the agitator cleaner.

Abstract: A vacuum cleaner having a base, an agitator cleaner, an agitator, and a motor. The agitator extends in a longitudinal direction and is mounted to the base to rotate about a longitudinal axis of the agitator and to move between a first position in which the agitator is spaced from the agitator cleaner and a second position in which the agitator engages the agitator cleaner. The motor is operatively associated with the base and configured to rotate the agitator about the longitudinal axis of the agitator while the agitator is in the second position to remove debris from the agitator by interaction between the agitator and the agitator cleaner.

Abstract: A vacuum cleaner having a base, an agitator, a motor, an agitator cleaner, first and second support assemblies, and an actuator. The agitator cleaner is movable to be spaced from the agitator or to engage the agitator to remove debris while the motor rotates the agitator. The support assemblies collectively support the base on a surface to be cleaned, and the first support assembly is movable between a raised position in which the agitator is proximal to the surface and a lowered position in which the agitator is spaced from the surface. The actuator is movable between an idle position and an operative position. The actuator has a first controller to move the agitator cleaner into the first position when the actuator is in the idle position, and a second controller to move the first support assembly to the lowered position when the actuator is in the operative position.

Abstract: A vacuum cleaner dirt collection assembly having a housing, an air inlet and air outlet connected to the housing and a cyclone chamber inside the housing. The cyclone chamber has top and bottom walls, and an outer wall joining the top and bottom walls to form a generally enclosed space. The outer wall has a helical guide channel extending radially outward from the adjacent portion of the outer wall. An inner wall, located inside the enclosed space, has a generally cylindrical or frustroconical surface having one or more openings fluidly connecting the enclosed space to the air outlet. A separator plate is located inside the enclosed space at a location between the top and bottom walls. The separator plate extends towards the outer wall and is spaced from the outer wall by a gap.

Abstract: This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof.

Abstract: A vacuum cleaner having a base, an agitator, a motor, an agitator cleaner, first and second support assemblies, and an actuator. The agitator cleaner is movable to be spaced from the agitator or to engage the agitator to remove debris while the motor rotates the agitator. The support assemblies collectively support the base on a surface to be cleaned, and the first support assembly is movable between a raised position in which the agitator is proximal to the surface and a lowered position in which the agitator is spaced from the surface. The actuator is movable between an idle position and an operative position. The actuator has a first controller to move the agitator cleaner into the first position when the actuator is in the idle position, and a second controller to move the first support assembly to the lowered position when the actuator is in the operative position.

Abstract: Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of direct compressed with specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus present formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable in vitro dissolution profile.

Abstract: A vacuum cleaner dirt collection assembly having a housing, an air inlet and air outlet connected to the housing and a cyclone chamber inside the housing. The cyclone chamber has top and bottom walls, and an outer wall joining the top and bottom walls to form a generally enclosed space. The outer wall has a helical guide channel extending radially outward from the adjacent portion of the outer wall. An inner wall, located inside the enclosed space, has a generally cylindrical or frustroconical surface having one or more openings fluidly connecting the enclosed space to the air outlet. A separator plate is located inside the enclosed space at a location between the top and bottom walls. The separator plate extends towards the outer wall and is spaced from the outer wall by a gap.

Abstract: The present invention provides processes for making and forms of solid dispersions of pharmaceutical active ingredients.

Abstract: This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof.

Abstract: Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of direct compressed with specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus present formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable in vitro dissolution profile.

Abstract: An apparatus in one example has an analytical environment for mashup data having visual analysis metaphors, and linking and correlation functionality among the visual analysis metaphors. A system may have: at least one store having a predetermined floor plan layout; at least one predetermined location on the predetermined floor plan layout for displaying at least one product; analytical environment for mashup data having visual analysis metaphors, the mashup data formed from data indiciative of the predetermined floor plan layout, and data indicated of sales of the at least one product; and linking and correlation functionality among the visual analysis metaphors through a web browser. In one example, a plurality of products may be positioned on a plurality of shelves, and may be depicted in a geographical display. Sales of each product may be depicted in a in time line display that is linked to the geographical display.

Abstract: A process for preparing solid dosage forms that contain poorly compressible therapeutic compound. The process, for example, provides for the inventive use of an extruder, especially a twin screw extruder, to melt granulate a therapeutic compound(s) with a granulation excipient.

Abstract: Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of being directly compressed with specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus presents formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable in vitro dissolution profile.

Abstract: The present invention relates to galenic formulations wherein the active ingredient aliskiren, preferably, a hemi-fumarate salt thereof, alone or in combination with another active ingredient, is melt-granulated and is present in an amount of more than 20% by weight based on the total weight of the oral dosage form, as well as a process of preparing said solid oral dosage form.

Abstract: This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof.

Abstract: A process for manufacturing solid oral dosage forms in an equipment train that comprises multiple pieces of apparatus designed for unit operations, such as blending, extruding, cooling, milling and finishing. The equipment in the equipment train allow for the transfer of raw materials and intermediate-processed materials from one apparatus to the next using transfer means, for example, gravity, vacuum, belts, and the like.

Abstract: The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component a) of 80% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component b) of 25% or more after 30 minutes, and 40% or more after 60 minutes at pH 4.5.

Abstract: The present invention provides processes for making and forms of solid dispersions of pharmaceutical active ingredients.

Abstract: The subject invention provides a pharmaceutical tablet formulation comprising per unit dosage form e.g.